A phase I, open-label dose-escalation trial of weekly (qw) BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody, in patients (pts) with advanced/metastatic solid tumors.

Affiliation auteurs!!!! Error affiliation !!!!
TitreA phase I, open-label dose-escalation trial of weekly (qw) BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody, in patients (pts) with advanced/metastatic solid tumors.
Type de publicationJournal Article
Year of Publication2018
AuteursIsambert N, Elez E, Zanetta S, Matos I, Nazabadioko S, Xue W, Carriere P, Tabernero J
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume36
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2018.36.15_suppl.e24013